Stieh, Daniel JKing, Deborah FKlein, KatjaLiu, PinghuangShen, XiaoyingHwang, Kwan KiFerrari, GuidoMontefiori, David CHaynes, BartonPitisuttithum, PunneeKaewkungwal, JaranitNitayaphan, SorachaiRerks-Ngarm, SupachaiMichael, Nelson LRobb, Merlin LKim, Jerome HDenny, Thomas NTomaras, Georgia DShattock, Robin J2017-06-012017-06-012014-10-02https://hdl.handle.net/10161/14673BACKGROUND: Antibody mediated viral aggregation may impede viral transfer across mucosal surfaces by hindering viral movement in mucus, preventing transcytosis, or reducing inter-cellular penetration of epithelia thereby limiting access to susceptible mucosal CD4 T cells and dendritic cells. These functions may work together to provide effective immune exclusion of virus from mucosal tissue; however little is known about the antibody characteristics required to induce HIV aggregation. Such knowledge may be critical to the design of successful immunization strategies to facilitate viral immune exclusion at the mucosal portals of entry. RESULTS: The potential of neutralizing and non-neutralizing IgG and IgA monoclonals (mAbs) to induce HIV-1 aggregation was assessed by Dynamic light scattering (DLS). Although neutralizing and non-neutralizing IgG mAbs and polyclonal HIV-Ig efficiently aggregated soluble Env trimers, they were not capable of forming viral aggregates. In contrast, dimeric (but not monomeric) IgA mAbs induced stable viral aggregate populations that could be separated from uncomplexed virions. Epitope specificity influenced both the degree of aggregation and formation of higher order complexes by dIgA. IgA purified from serum of uninfected RV144 vaccine trial responders were able to efficiently opsonize viral particles in the absence of significant aggregation, reflective of monomeric IgA. CONCLUSIONS: These results collectively demonstrate that dIgA is capable of forming stable viral aggregates providing a plausible basis for testing the effectiveness of aggregation as a potential protection mechanism at the mucosal portals of viral entry.Antibodies, MonoclonalHIV AntibodiesHIV-1HumansImmunoglobulin AImmunoglobulin GJournal article1742-4690